Fri. Aug 19th, 2022
Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. The detailed market research, industry sector growth and development, and new product introductions covered in this report on the Acute Myeloid Leukemia Market are of great assistance to the important new commercial players joining the market.

This Acute Myeloid Leukemia Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Acute Myeloid Leukemia Market report analysis.

Regions Covered in the Report-

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Click the link to get a Sample Copy of the Report before purchase: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market

Acute Myeloid Leukemia: An Overview

Acute Myeloid Leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized by a clonal proliferation and impaired differentiation of myeloid precursors with diverse outcomes. It is the fastest growing cancer that occurs when the bone marrow begins to form cells that have not yet completely matured as blasts. These cells crowd the bone marrow, preventing it from making normal blood cells and the abnormal (leukemia) cells begin to crowd out the normal white blood cells, red blood cells, and platelets that the body needs. In AML, the bone marrow also makes abnormal red cells and platelets, and thus the blood cells do not develop, and it gets difficult to ward off infections.

Key highlights of the Acute Myeloid Leukemia Market Report

  • AML accounts for <3% of all cancers, and 25% of all leukemia in adults. Worldwide, the incidence of AML was reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years.
  • The incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people age <65 years was only 1.8 per 100,000 persons, whereas the incidence rate in people age 65 years was 17 per 100,000 persons. (Desehler et al.)
  • According to a cross-national study using US and England data, it has been found that the overall risk of mortality for AML was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis.

Acute Myeloid Leukemia Epidemiology Insights

According to the cross-national study by Xie et al., the survival patterns in individuals diagnosed with AML reported the mortality risk, which varied substantially across AML subtypes between England and US. This difference was significant in AML inv (16), which showed a higher risk of mortality than their US counterparts. In other subtypes, the observed mortality rate reported in AML was with minimal differentiation, AML without maturation, and AML with maturation was [0.54, 0.25–1.17; 0.38, 0.20–0.74, and 0.52, 0.31–0.86, respectively] not differed significantly.

Acute Myeloid Leukemia Epidemiology Segmentation in the 7MM

  • Total Incidence
  • Age-Specific Cases
  • Diagnosed and Treatable Cases
  • Relapsed/Refractory Cases

Acute Myeloid Leukemia Treatment Market

Traditionally, the standardized treatment was chemotherapy which can be divided into intensive chemotherapy and non-intensive. The intensive chemotherapies are divided into two phases i.e. remission induction followed by post-remission consolidation-based therapy. The induction therapy includes drugs such as Cytarabine, Daunorubicin, Idarubicin, and Fludarabine either given alone or in combinatorial doses. Consolidation therapy is given in such cases where induction therapy failed to work, with drugs such as Etoposide, Amsacrine, and Mitoxantrone. Age, performance status, prognostic indicators were the major resistance factors to chemotherapy effectiveness.

Acute Myeloid Leukemia Market Insights

Several AML cases might become resistant due to cytogenetic and molecular genetic abnormalities with markedly different outcomes with available therapies. Given the challenges in the treatment of both primary and refractory/relapsed AML, researchers have focused to identify specific targets that could be exploited as alternatives, such as the development of targeted therapies. Genomic investigations of AML identified, i.e., several genes are recurrently mutated, leading to predictive biomarkers, and new therapeutic targets for the enlargement of therapies.

Acute Myeloid Leukemia Market Outlook

AML is the most common leukemia affecting adults and poses a major medical challenge with increased mortality and morbidity. Once diagnosed, the treatment usually needs to start as quickly as possible, as AML progresses very quickly. The treatment depends on age, risk factors, and the sub-types of AML. The main aim of treatment for AML is to cure it and to achieve remission of leukemia cells.

Make an Enquiry Before Buying- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market

Table of Content

  1. Key Insights
  2. Executive Summary
  3. Competitive Intelligence Analysis for Acute Myeloid Leukemia
  4. Acute Myeloid Leukemia Market Overview at a Glance
  5. Acute Myeloid Leukemia Disease Background and Overview
  6. Patient Journey
  7. Acute Myeloid Leukemia Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Acute Myeloid Leukemia Unmet Needs
  10. Key Endpoints of Acute Myeloid Leukemia Treatment
  11. Acute Myeloid Leukemia Marketed Products
  12. Acute Myeloid Leukemia Emerging Therapies
  13. Acute Myeloid Leukemia Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Acute Myeloid Leukemia Market Outlook
  16. Access and Reimbursement Overview of Acute Myeloid Leukemia
  17. KOL Views
  18. Acute Myeloid Leukemia Market Drivers
  19. Acute Myeloid Leukemia Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

Acute Myeloid Leukemia Market Report Highlights

  • In the coming years, the Acute Myeloid Leukemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Myeloid Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Acute Myeloid Leukemia. The launch of emerging therapies will significantly impact the Acute Myeloid Leukemia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acute Myeloid Leukemia
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia market
  • To understand the future market competition in the Acute Myeloid Leukemia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia market
  • To understand the future market competition in the Acute Myeloid Leukemia market

Get in touch with our Business Expert @ Business Consulting Services | Biotech Consulting | Technical Due Diligence Firms

Trending & Popular Market Research Reports 2022 by Delveinsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash

[email protected]

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *